How Is Prostate Cancer Treatment in Japan Different From Korea? A 2026 Comparison

Your question about "prostate cancer treatment in Japan" can't be answered precisely, as this note doesn't contain country-specific statistics or clinical guidelines for Japan. However, we can explain this based on the internationally recognized standard prostate cancer treatment framework (risk-group-based approach) that international patients commonly reference, along with the treatment pathway available in Korea.

Key Summary

• Regardless of country, the international standard for prostate cancer is to determine treatment based on risk group (low-risk, intermediate-risk, high-risk, metastatic) — there isn't a separate treatment approach unique to any one country.
• Korea's 5-year relative survival rate for prostate cancer is 96.9% (National Cancer Registration Statistics, 2019–2023), while the US SEER figure is 98.2% (2016–2022). Both are national-level statistics, not individual hospital outcomes.
• Prostate cancer is one of the rare cancers where active surveillance — monitoring without treatment — is a standard option for low-risk cases.
• For intermediate-risk and above, both surgery (robotic radical prostatectomy) and radiation therapy (IMRT, SBRT, carbon-ion therapy, etc.) are standard options, chosen based on risk group and individual circumstances.
• Korea has extensive experience with robotic prostatectomy, and has offered carbon-ion therapy since 2023.

Is There a Treatment Approach Unique to Japan?

• This note does not include Japan's national statistics or clinical guidelines, so there's no basis here to describe a separate 'Japanese-style' treatment system. That said, prostate cancer treatment internationally follows a common framework: risk group is determined by combining PSA level, Gleason score (Grade Group 1–5), and stage, then factoring in age, life expectancy, and comorbidities.
• So the key question isn't 'which country's treatment is better' but rather 'what treatment fits my risk group' — a standard that applies regardless of country.

How Does Standard Treatment Differ by Risk Group?

• For low-risk disease (low PSA, lowest Grade Group, small tumor confined within the prostate), active surveillance is standard — monitoring at set intervals with PSA, MRI, and repeat biopsy if needed. Treatment begins only if signs of progression appear.
• For intermediate-risk disease, both radical prostatectomy and radiation therapy are standard options; the choice often comes down to differences in side-effect profile rather than differences in outcome.
• For high-risk or locally advanced disease, standard approaches include removing pelvic lymph nodes along with the prostate during surgery, adding radiation, or combining radiation with several years of hormone therapy.
• For metastatic disease, the standard has shifted to combining hormone therapy from the start with anti-androgen agents or chemotherapy. If bone metastases are present, bone-protective medication and palliative radiation for pain relief are added.

What Steps Lead From Diagnosis to Treatment Direction?

1. Step 1: If PSA blood test levels are elevated or digital rectal exam finds an abnormality, prostate MRI is performed first.
2. Step 2: If MRI reveals a suspicious area, a targeted MRI-fusion biopsy of that site is performed to obtain the Gleason score and Grade Group.
3. Step 3: MRI is used to check whether the tumor has invaded beyond the prostate capsule; for higher-risk cases, a bone scan or PSMA PET is used to check for metastasis.
4. Step 4: PSA, Grade Group, and stage are combined to determine the risk group, and — factoring in age, life expectancy, and comorbidities — the direction is set among active surveillance, surgery, radiation therapy, or hormone therapy.
5. Step 5: After treatment, PSA is measured at set intervals to monitor for recurrence.

FAQ — Can Treatment Started Abroad Be Continued Seamlessly in Korea?

Even if hormone therapy injections were being administered abroad, the type and interval of the injection and any accompanying oral medication can be carried over into a prescription plan. Since available medications vary by country, checking for substitutable alternatives is common practice. However, the specific decision on how to transition treatment is made based on existing records — PSA history, MRI, and biopsy results (Gleason score).

FAQ — Which Is Better, Surgery or Radiation (Including Carbon-Ion Therapy)?

There isn't a 'better' option — there's a 'right fit' option. Robotic radical prostatectomy is widely used for localized prostate cancer surgery and is known to be favorable for nerve preservation; hospital stays are typically 5–7 days. Carbon-ion therapy has been available in Korea since 2023, with localized prostate cancer typically treated in around 12 sessions; eligibility depends on prior radiation history, presence of an artificial hip joint, and bowel/bladder condition. Either way, the choice is made based on age, risk group, priorities regarding incontinence/sexual function, and urinary status.

Sources and Notes

• This article was written based on National Cancer Registration Statistics 2019–2023 (Korea Central Cancer Registry, National Cancer Center), US SEER 2016–2022, the National Cancer Information Center, and NCCN patient guidelines. It does not include Japan's individual statistics or guidelines.
• This content is provided for general medical information purposes only; diagnosis, treatment methods, and outcomes may vary depending on individual condition. Accurate diagnosis and treatment should always be determined through consultation with a medical professional.